In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models
| Autor: | Steven L. Yoder, Carl L. Heifetz, Jeffrey W. Gage, Mark A. Meservey, Sara A. Wold, Michael A. Cohen, Gregory E. Roland, Gail B. Mailloux |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Microbiology (medical)
Staphylococcus aureus Haemophilus Infections medicine.drug_class Cephalosporin Administration Oral Microbial Sensitivity Tests medicine.disease_cause beta-Lactamases Haemophilus influenzae Microbiology Mice Ampicillin medicine Animals Subcutaneous abscess Cefdinir Cefpodoxime Proxetil business.industry General Medicine Staphylococcal Infections Cephalosporins Infectious Diseases Female business Cefaclor medicine.drug |
| Zdroj: | Diagnostic Microbiology and Infectious Disease. 18:41-47 |
| ISSN: | 0732-8893 |
| DOI: | 10.1016/0732-8893(94)90132-5 |
| Popis: | Cefdinir (FK482), a new oral cephalosporin, displayed potent oral activity versus induced infections in mice. In studies using beta-lactamase-nonproducing (beta LAC-) and -producing (beta LAC+) Staphylococcus aureus strains, respective PD50s (in mg/kg) were 11 and 24 for preventing subcutaneous abscess and 2.7 and 2.3 for preventing lethal systemic infection. In studies using beta LAC- and beta LAC+ Haemophilus influenzae, respective PD50s were 5.8 and 3.1 for preventing lethal systemic infection. Time-kill studies versus H. influenzae showed that 6- to 12-mg/kg dosing was effective in reducing viable counts of these strains in blood by > or = 100-fold by 24 h after challenge. This in vivo performance was comparable to or exceeded values generated by cefaclor, cefpodoxime proxetil, and ampicillin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|